rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma.
|
28475671 |
2017 |
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma.
|
28475671 |
2017 |
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Researchers retrospectively reviewed medical records of all patients at our institution with surgically incurable BRAF V600E mutated stage III or limited stage IV melanoma treated with induction vemurafenib, stopped electively during ongoing response, followed by consolidative radiation therapy with or without intervening surgery to debulk nodal metastases.
|
25746037 |
2015 |
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Researchers retrospectively reviewed medical records of all patients at our institution with surgically incurable BRAF V600E mutated stage III or limited stage IV melanoma treated with induction vemurafenib, stopped electively during ongoing response, followed by consolidative radiation therapy with or without intervening surgery to debulk nodal metastases.
|
25746037 |
2015 |
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) or dabrafenib and placebo.
|
25265492 |
2014 |
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) or dabrafenib and placebo.
|
25265492 |
2014 |
rs121913227
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutation-positive unresectable stage IIIC or stage IV melanoma.
|
26037941 |
2015 |
rs121913255
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Subsequently, we quantified ctDNA ((V600E)BRAF,(V600K)BRAF or (Q61H)NRAS) in 6 stage IV melanoma patients across several time points during their treatment course.
|
26095797 |
2015 |